Impact of sustained virologic response on chronic kidney disease progression in hepatitis C

Table 2 Baseline characteristics for patients undergoing treatment for hepatitis C virus at the West Los Angeles Veterans Administration compared to patients with hepatitis C virus who did not undergo treatment

	All patients (n = 523)	Control patients (n = 439)	P value
Age (mean, yr) (SE)	62.8 (0.3)	63.2 (0.3)	0.13
Gender (%)
Male	97.9	98.1	0.75
Female	2.1	1.9
Ethnicity (%)
White	53.2	55.4	0.3
Black or African American	33.3	35.1
American Indian or Alaska Native	2.1	2.5
Asian	0.8	0.5
Native Hawaiian or other pacific islander	1.0	0.9
Unknown/declined to answer	9.8	5.7
Cirrhosis (%)
Non-cirrhotic	51.4	72.0	0.001a
Cirrhosis	48.6	28.0
HCV genotype (%)
HCV genotype 1a	53.2	55.9	0.31
HCV genotype 1b	28.1	22.8
HCV genotype 2	9.2	11.8
HCV genotype 3	7.6	6.7
HCV genotype 4	1.1	1.7
HCV genotype 6	0.2	0.0
Obesity (%)
BMI < 30	54.3	63.3	0.005a
Obese	45.7	36.7
Hypertension (%)
No hypertension	33.8	26.7	0.02a
Hypertension	68.5	73.3
Diabetes (%)
No diabetes	68.5	64.0	0.15
Diabetes	31.5	36.0
Congestive heart failure (%)
No congestive heart failure	95.8	90.4	0.001a
Congestive heart failure	4.2	9.6
Coronary artery disease (%)
No coronary artery disease	89.7	88.4	0.46
Coronary artery disease	10.1	11.6
Peripheral arterial disease (%)
No peripheral arterial disease	97.1	95.2	0.09
Peripheral arterial disease	2.9	4.8
Baseline CKD before treatment (%)
Stage 1 CKD	50.3	47.1	0.56
Stage 2 CKD	41.7	37.8
Stage 3 CKD	7.8	5.4
Stage 4 CKD	0.2	0.4
Diuretic use (%)
No diuretic use	70.2	67.2	0.3
Diuretic use	29.8	32.8

^aSignificant P-value, P < 0.05. CKD: Chronic kidney disease; HCV: Hepatitis C virus; BMI: Body mass index.